MAP3K20

Across TCGA pan-cancer cohorts, MAP3K20 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of MAP3K20’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MAP3K20 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAP3K20 is over-expressed in tumor, although a few such as BLCA and UCEC show the opposite, repressed pattern.

KIRC, BLCA, and HNSC are the cancer types where MAP3K20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP3K20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+0.980	<.001	10	view →
BLCA	Male	All	−2.634	<.001	8	view →
HNSC	Female	III,IV	+1.438	<.001	8	view →
UCEC	All	All	−2.187	<.001	6	view →
BRCA	All	III,IV	−1.071	<.001	6	view →
LUAD	Female	III,IV	−1.058	<.001	6	view →
CHOL	Male	All	+2.111	<.001	5	view →
LIHC	All	All	+0.531	<.001	5	view →
COAD	Female	II,III,IV	+0.925	.006	4	view →
THCA	All	All	−0.367	.009	3	view →
STAD	Female	All	−2.129	.006	2	view →
KIRP	All	II,III,IV	+0.824	.023	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

MAP3K20–KIRC

Open the KIRC breakdown →